semaglutide hypertension and effects on brain as a Cornerstone Therapy in Obesity: Clinical Pharmacological Insights semaglutide intracranial Recurrent Idiopathic – semaglutide for hypertension Semaglutide: A – Semaglutide cardiovascular outcomes align more

In the 2025 SURMOUNT-5 trial, adults with obesity but without diabetes received tirzepatide or semaglutide once weekly for 72 weeks

doi: 10.1016/j.scitotenv.2023.165832 234 NeedhamC

Do not transfer medication to different containers

Plateaus: Your weight loss progress might stall because the metabolic benefits of the medication have weakened

Insurance companies need to determine coverage

Imaging studies revealed diminished activation in brain regions such as the insula, putamen, and orbitofrontal cortex when exposed to high-calorie food cues, suggesting that GLP1-S reshapes both physiological hunger responses and the motivational aspects of eating